Axogen (AXGN) vs Electromed (ELMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen (AXGN) has outperformed Electromed (ELMD) over the past year, gaining 110.8% versus a gain of 10.7%. Over five years, AXGN leads with a +165.6% price change compared with +153.0% for ELMD. Axogen is the larger company by market cap ($2.12 billion vs $230.4 million), about 9.2 times the size.
On valuation, Electromed trades at a lower forward P/E (45.6x vs 52.6x for Axogen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | ELMD |
|---|---|---|
| Share price | $36.18 | $27.80 |
| Market cap | $2.12B | $230.38M |
| 1-day change | +0.39% | -1.42% |
| YTD return | +10.54% | -4.53% |
| 1-year return | +110.84% | +10.67% |
| 5-year return | +165.64% | +152.96% |
| P/E ratio (TTM) | — | 21.38 |
| Forward P/E | 52.59 | 45.57 |
| EPS (TTM) | $-0.67 | $1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.91 | $47.40 |
| 52-week low | $15.27 | $23.01 |
| Distance from 52-week high | -31.62% | -41.35% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +48.76% | +74.46% |
| Average volume | 1.22M | 104.86K |
| Shares outstanding | 58.67M | 8.29M |
| Employees | 622 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 9.2 times larger than Electromed by market value ($2.12B vs $230.38M).
- AXGN has outperformed ELMD by 100.2 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
AXGN vs ELMD FAQ
Which is bigger, Axogen or Electromed?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $230.38M for Electromed (ELMD).
Which stock has performed better over the past year, AXGN or ELMD?
AXGN returned +110.84% over the past 12 months, compared with +10.67% for ELMD (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and Electromed in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.